These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

86 related items for PubMed ID: 1937169

  • 1. Pharmacokinetics of high-dose cyclophosphamide for bone marrow transplantation.
    Fasola G, Lo Greco P, Calori E, Zilli M, Verlicchi F, Motta MR, Ricci P, Baccarani M, Tura S.
    Haematologica; 1991; 76(2):120-5. PubMed ID: 1937169
    [Abstract] [Full Text] [Related]

  • 2. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity.
    Hassan M, Ljungman P, Ringdén O, Hassan Z, Oberg G, Nilsson C, Békassy A, Bielenstein M, Abdel-Rehim M, Georén S, Astner L.
    Bone Marrow Transplant; 2000 May; 25(9):915-24. PubMed ID: 10800057
    [Abstract] [Full Text] [Related]

  • 3. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
    Chen TL, Passos-Coelho JL, Noe DA, Kennedy MJ, Black KC, Colvin OM, Grochow LB.
    Cancer Res; 1995 Feb 15; 55(4):810-6. PubMed ID: 7850794
    [Abstract] [Full Text] [Related]

  • 4. Urinary excretion and pharmacokinetics of acrolein and its parent drug cyclophosphamide in bone marrow transplant patients.
    Al-Rawithi S, El-Yazigi A, Ernst P, Al-Fiar F, Nicholls PJ.
    Bone Marrow Transplant; 1998 Sep 15; 22(5):485-90. PubMed ID: 9733272
    [Abstract] [Full Text] [Related]

  • 5. Phase I study of busulfan, cyclophosphamide, and timed sequential escalating doses of cytarabine followed by bone marrow transplantation.
    Geller RB, Myers S, Devine S, Larson RA, Williams SF, Park CL, O'Toole K, Chandler C, Topper RL.
    Bone Marrow Transplant; 1992 Jan 15; 9(1):41-7. PubMed ID: 1543948
    [Abstract] [Full Text] [Related]

  • 6. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation.
    Sladek NE, Doeden D, Powers JF, Krivit W.
    Cancer Treat Rep; 1984 Oct 15; 68(10):1247-54. PubMed ID: 6395951
    [Abstract] [Full Text] [Related]

  • 7. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
    Chen TL, Kennedy MJ, Anderson LW, Kiraly SB, Black KC, Colvin OM, Grochow LB.
    Drug Metab Dispos; 1997 May 15; 25(5):544-51. PubMed ID: 9152592
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy.
    Anderson LW, Chen TL, Colvin OM, Grochow LB, Collins JM, Kennedy MJ, Strong JM.
    Clin Cancer Res; 1996 Sep 15; 2(9):1481-7. PubMed ID: 9816324
    [Abstract] [Full Text] [Related]

  • 10. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May 15; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 11. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation.
    Schultz KR, Nevill TJ, Balshaw RF, Toze CL, Corr T, Currie CJ, Strong DK, Keown PA.
    Bone Marrow Transplant; 2000 Sep 15; 26(5):545-51. PubMed ID: 11019845
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent.
    Muus P, Donnelly P, Schattenberg A, Linssen P, Minderman H, Dompeling E, de Witte T.
    Semin Oncol; 1993 Dec 15; 20(6 Suppl 8):47-52. PubMed ID: 8290971
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics of high-dose VP-16: 6-hour infusion versus 34-hour infusion.
    Mross K, Bewermeier P, Reifke J, Krüger W, Stockschläder M, Zander A, Hossfeld DK.
    Bone Marrow Transplant; 1994 Apr 15; 13(4):423-30. PubMed ID: 8019466
    [Abstract] [Full Text] [Related]

  • 19. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W, Liliemark JO, Adams TM, Nowak B, Estey E, Kantarjian H, Keating MJ.
    Cancer Res; 1987 Jun 01; 47(11):3005-11. PubMed ID: 3471322
    [Abstract] [Full Text] [Related]

  • 20. Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies.
    Williams CB, Day SD, Reed MD, Copelan EA, Bechtel T, Leather HL, Wingard JR, Abbott BL, Abhyankar S, McGuirk JP.
    Biol Blood Marrow Transplant; 2004 Sep 01; 10(9):614-23. PubMed ID: 15319773
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.